Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing

Journal of Experimental Medicine

Volumn 211, Issue 9, 2014, Pages 1893-1904

  Wells, Timothy J ^a   Whitters, Deborah ^a,b   Sevastsyanovich, Yanina R ^a   Heath, Jennifer N ^a   Pravin, John ^a   Goodall, Margaret ^a   Browning, Douglas F ^a   O'Shea, Matthew K ^c   Cranston, Amy ^d   De Soyza, Anthony ^e   Cunningham, Adam F ^a   MacLennan, Calman A ^a   Henderson, Ian R ^a   Stockley, Robert A ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; HUMAN PLACENTA LACTOGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN M; LIPOPOLYSACCHARIDE; O ANTIGEN; PROTEIN A; PROTEIN G;

ANTIBODY DEPENDENT ENHANCEMENT; ANTIGEN BINDING; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; BLOCKING FACTOR; BLOOD SAMPLING; BRONCHIECTASIS; CLINICAL ARTICLE; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME MECHANISM; GRAM NEGATIVE BACTERIUM; HOST RESISTANCE; HUMAN; LUNG FUNCTION; LUNG INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY FUNCTION; RESPIRATORY TRACT INFECTION; SERUM BACTERICIDAL ACTIVITY;

ANTIBODIES, BLOCKING; ANTIBODY-DEPENDENT ENHANCEMENT; BLOOD BACTERICIDAL ACTIVITY; BRONCHIECTASIS; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNOGLOBULIN G; O ANTIGENS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 84906569137     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20132444     Document Type: Article

References (37)

1. Bilton, D. 2008. Update on non-cystic fibrosis bronchiectasis. Curr. Opin. Pulm. Med. 14:595-599. http://dx.doi.org/10.1097/MCP.0b013e328312ed8c
2. Brown, E.J., K.A. Joiner, and M.M. Frank. 1983. The role of complement in host resistance to bacteria. Springer Semin. Immunopathol. 6:349-360. http://dx.doi.org/10.1007/BF02116279
3. Browning, D.F., D.E. Whitworth, and D.A. Hodgson. 2003. Light-induced carotenogenesis in Myxococcus xanthus: functional characterization of the ECF sigma factor CarQ and antisigma factor CarR. Mol. Microbiol. 48:237-251. http://dx.doi.org/10.1046/j.1365-2958.2003.03431.x
4. Brüggemann, M., G.T. Williams, C.I. Bindon, M.R. Clark, M.R. Walker, R. Jefferis, H. Waldmann, and M.S. Neuberger. 1987. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166:1351-1361. http://dx.doi.org/10.1084/jem.166.5.1351
5. Cryz, S.J. Jr., J.C. Sadoff, A.S. Cross, and E. Fürer. 1989. Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans. Antibiot Chemother (1971). 42:177-183.
6. Cryz, S.J. Jr., A. Lang, A. Rüdeberg, J. Wedgwood, J.U. Que, E. Fürer, and U. Schaad. 1997. Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Behring Inst. Mitt. 98:345-349.
7. Döring, G., and G.B. Pier. 2008. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine. 26:1011-1024. http://dx.doi.org/10.1016/j.vaccine.2007.12.007
8. Fick, R.B. Jr., J. Olchowski, S.U. Squier, W.W. Merrill, and H.Y. Reynolds. 1986. Immunoglobulin-G subclasses in cystic fibrosis. IgG2 response to Pseudomonas aeruginosa lipopolysaccharide. Am. Rev. Respir. Dis. 133:418-422.
9. Flipse, J., J. Wilschut, and J.M. Smit. 2013. Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans. Traffic. 14:25-35.
10. Gondwe, E.N., M.E. Molyneux, M. Goodall, S.M. Graham, P. Mastroeni, M.T. Drayson, and C.A. MacLennan. 2010. Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans. Proc. Natl. Acad. Sci. USA. 107:3070-3075. http://dx.doi.org/10.1073/pnas.0910497107
11. Guttman, R.M., and B.A. Waisbren. 1975. Bacterial blocking activity of specific IgG in chronic Pseudomonas aeruginosa infection. Clin. Exp. Immunol. 19:121-130.
12. Halstead, S.B., and E.J. O'Rourke. 1977. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J. Exp. Med. 146:201-217. http://dx.doi.org/10.1084/jem.146.1.201
13. Halstead, S.B., S. Mahalingam, M.A. Marovich, S. Ubol, and D.M. Mosser. 2010. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect. Dis. 10:712-722. http://dx.doi.org/10.1016/S1473-3099(10)70166-3
14. Hann, S., and D.S. Holsclaw. 1976. Interactions of Pseudomonas aeruginosa with immunoglobulins and complement in sputum. Infect. Immun. 14: 114-117.
15. Hill, S.L., J.L. Mitchell, D. Burnett, and R.A. Stockley. 1998. IgG subclasses in the serum and sputum from patients with bronchiectasis. Thorax. 53:463-468. http://dx.doi.org/10.1136/thx.53.6.463
16. Hornick, D.B., and R.B. Fick Jr. 1990. The immunoglobulin G subclass composition of immune complexes in cystic fibrosis. Implications for the pathogenesis of the Pseudomonas lung lesion. J. Clin. Invest. 86:1285-1292. http://dx.doi.org/10.1172/JCI114836
17. Jefferis, R., C.B. Reimer, F. Skvaril, G.G. de Lange, D.M. Goodall, T.L. Bentley, D.J. Phillips, A. Vlug, S. Harada, J. Radl, et al. 1992. Evaluation of monoclonal antibodies having specificity for human IgG subclasses: results of the 2nd IUIS/WHO collaborative study. Immunol. Lett. 31:143-168. http://dx.doi.org/10.1016/0165-2478(92)90141-A
18. Kronborg, G., T. Pressler, A. Fomsgaard, C. Koch, and N. Høiby. 1993. Specific IgG2 antibodies to Pseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis. Infection. 21:297-302. http://dx.doi.org/10.1007/BF01712448
19. Langford, D.T., and J. Hiller. 1984. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis-three year results. Arch. Dis. Child. 59:1131-1134. http://dx.doi.org/10.1136/adc.59.12.1131
20. Leyton, D.L., Y.R. Sevastsyanovich, D.F. Browning, A.E. Rossiter, T.J. Wells, R.E. Fitzpatrick, M. Overduin, A.F. Cunningham, and I.R. Henderson. 2011. Size and conformation limits to secretion of disulfide-bonded loops in autotransporter proteins. J. Biol. Chem. 286:42283-42291. http://dx.doi.org/10.1074/jbc. M111.306118
21. MacLennan, C.A., J.J. Gilchrist, M.A. Gordon, A.F. Cunningham, M. Cobbold, M. Goodall, R.A. Kingsley, J.J. van Oosterhout, C.L. Msefula, W.L. Mandala, et al. 2010. Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults. Science. 328:508-512. http://dx.doi.org/10.1126/science.1180346
22. Martínez-García, M.A., M. Perpiñá-Tordera, P. Román-Sánchez, and J.J. Soler-Cataluña. 2005. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest. 128:739-745. http://dx.doi.org/10.1378/chest.128.2.739
23. Martínez-García, M.A., J.J. Soler-Cataluña, M. Perpiñá-Tordera, P. Román-Sánchez, and J. Soriano. 2007. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 132:1565-1572. http://dx.doi.org/10.1378/chest.07-0490
24. Moffitt, M.C., and M.M. Frank. 1994. Complement resistance in microbes. Springer Semin. Immunopathol. 15:327-344. http://dx.doi.org/10.1007/BF01837364
25. Normansell, D.E. 1987. Human immunoglobulin subclasses. Diagn. Clin. Immunol. 5:115-128.
26. Parham, N.J., U. Srinivasan, M. Desvaux, B. Foxman, C.F. Marrs, and I.R. Henderson. 2004. PicU, a second serine protease autotransporter of uropathogenic Escherichia coli. FEMS Microbiol. Lett. 230:73-83. http://dx.doi.org/10.1016/S0378-1097(03)00862-0
27. Pasteur, M.C., S.M. Helliwell, S.J. Houghton, S.C. Webb, J.E. Foweraker, R.A. Coulden, C.D. Flower, D. Bilton, and M.T. Keogan. 2000. An investigation into causative factors in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 162:1277-1284. http://dx.doi.org/10.1164/ajrccm.162.4.9906120
28. Pasteur, M.C., D. Bilton, and A.T. Hill. British Thoracic Society Non-CF Bronchiectasis Guideline Group. 2010. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 65:577. http://dx.doi.org/10.1136/thx.2010.142778
29. Pennington, J.E., H.Y. Reynolds, R.E. Wood, R.A. Robinson, and A.S. Levine. 1975. Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis. Am. J. Med. 58:629-636. http://dx.doi.org/10.1016/0002-9343(75)90498-2
30. Raghunathan, D., T.J. Wells, F.C. Morris, R.K. Shaw, S. Bobat, S.E. Peters, G.K. Paterson, K.T. Jensen, D.L. Leyton, J.M. Blair, et al. 2011. SadA, a trimeric autotransporter from Salmonella enterica serovar Typhimurium, can promote biofilm formation and provides limited protection against infection. Infect. Immun. 79:4342-4352. http://dx.doi.org/10.1128/IAI.05592-11
31. Schroeder, H.W. Jr., and L. Cavacini. 2010. Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 125(2, Suppl 2):S41-S52. http://dx.doi.org/10.1016/j.jaci.2009.09.046
32. Siber, G.R., P.H. Schur, A.C. Aisenberg, S.A. Weitzman, and G. Schiffman. 1980. Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N. Engl. J. Med. 303: 178-182. http://dx.doi.org/10.1056/NEJM198007243030402
33. Taborda, C.P., J. Rivera, O. Zaragoza, and A. Casadevall. 2003. More is not necessarily better: prozone-like effects in passive immunization with IgG. J. Immunol. 170:3621-3630. http://dx.doi.org/10.4049/jimmunol.170.7.3621
34. Waisbren, B.A., and I. Brown. 1966. A factor in the serum of patients with persisting infection that inhibits the bactericidal activity of normal serum against the organism that is causing the infection. J. Immunol. 97:431-437.
35. Wells, T.J., O. Sherlock, L. Rivas, A. Mahajan, S.A. Beatson, M. Torpdahl, R.I. Webb, L.P. Allsopp, K.S. Gobius, D.L. Gally, and M.A. Schembri. 2008. EhaA is a novel autotransporter protein of enterohemorrhagic Escherichia coli O157:H7 that contributes to adhesion and biofilm formation. Environ. Microbiol. 10:589-604. http://dx.doi.org/10.1111/j.1462-2920.2007.01479.x
36. Whitters, D., and R. Stockley. 2012. Immunity and bacterial colonisation in bronchiectasis. Thorax. 67:1006-1013. http://dx.doi.org/10.1136/thoraxjnl-2011-200206
37. Wilson, C.B., P.W. Jones, C.J. O'Leary, D.M. Hansell, P.J. Cole, and R. Wilson. 1997. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur. Respir. J. 10:1754-1760. http://dx.doi.org/10.1183/09031936.97.10081754